EMA's CAT launches consultation on guideline on risk-based approach for ATMPs
This article was originally published in Clinica
Executive Summary
The Committee for Advanced Therapies at the European Medicines Agency has launched a five-month open consultation on a draft guideline on applying the risk-based approach to advanced therapy medicinal products (ATMPs).